芪苈强心胶囊联合尼可地尔治疗慢性心力衰竭的临床效果

Clinical effect of Qili Qiangxin Capsule combined with nicorandil in treatment of chronic heart failure

  • 摘要: 目的 探讨芪苈强心胶囊与尼可地尔联合治疗慢性心力衰竭的临床疗效。 方法 选取本院收治的慢性心力衰竭患者200例为研究对象,并随机分为治疗组及对照组,每组100例。全部患者均接受慢性心力衰竭的规范化药物治疗,对照组患者口服尼可地尔片,治疗组在对照组基础上联合口服芪苈强心胶囊, 4周为1个疗程,连续治疗3个疗程。观察2组患者的临床疗效、不良反应,并比较治疗前及治疗结束时2组患者心功能改善情况与实验室指标变化。 结果 治疗结束时,治疗组总有效率为95.00%, 高于对照组的81.00%, 差异有统计学意义(P<0.05); 治疗结束时, 2组患者左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)均较治疗前减小,左心室射血分数(LVEF)较治疗前增高,差异有统计学意义(P<0.05); 治疗组治疗结束时LVESD、LVEDD小于对照组, LVEF高于对照组,差异有统计学意义(P<0.05)。治疗结束时, 2组超敏C反应蛋白(hs-CRP)、肌钙蛋白Ⅰ(cTnⅠ)、B型利钠肽(BNP)水平均较治疗前下降,差异有统计学意义(P<0.05); 治疗组治疗结束时, hs-CRP、cTnⅠ及BNP指标均低于对照组,差异有统计学意义(P<0.05)。治疗期间, 2组均发生头痛、头晕、失眠等不良反应,但2组比较差异无统计学意义(P>0.05)。 结论 芪苈强心胶囊与尼可地尔联合治疗慢性心力衰竭的疗效确切,能够显著改善患者心功能,降低hs-CRP、cTnⅠ及BNP水平,且不会增加不良反应。

     

    Abstract: Objective To investigate the clinical efficacy of Qili Qiangxin Capsule combined with nicorandil in treatment of chronic heart failure. Methods A total of 200 patients with chronic heart failure in our hospital were randomly divided into control group and treatment group, with 100 cases in each group. All patients received normative drug therapy for chronic heart failure, the patients in control group orally took nicorandil tablets, and those in the treatment group orally administrated Qili Qiangxin Capsule based on the control group. Four weeks was a course of treatment, and the treatment was lased for 3 courses. The clinical efficacy and adverse reactions of two groups were observed. Before treatment and at the end of treatment, the changes of laboratory indexes and improvement of cardiac function were compared between two groups. Results At the end of treatment, the total effective rate of the treatment group was significantly higher than that of the control group(95.00% vs. 81.00%, P<0.05); at the end of treatment, left ventricular end-diastolic diameter(LVEDD)and left ventricular end-systolic diameter(LVESD)in the two groups were lower than those before treatment, and the left ventricular ejection fraction(LVEF)was increased, and there were statistical differences in two groups before and after treatment(P<0.05); at the end of treatment, the LVESD and LVEDD in the treatment group were smaller than those in control group, and the LVEF of the treatment group was higher than that of control group(P<0.05); at the end of - treatment, the high sensitivity C reactive protein(hs-CRP)and cardiac troponin Ⅰ(cTnⅠ), B-type natriuretic peptide(BNP)in two groups were significantly lower than those before treatment(P<0.05); at the end of treatment, the hs-CRP,cTnⅠ and BNP in the treatment group were significantly lower than those in the control group(P<0.05); adverse reactions such as headache, dizziness and insomnia in two groups were found during treatment, but no difference was seen in two groups(P>0.05). Conclusion QiliQiangxin Capsule combined with nicorandil in treatment of chronic heart failure has definite efficacy, which can significantly improve cardiac function, decrease the levels of hs-CRP, cTnⅠ and BNP, and will not increase adverse reactions.

     

/

返回文章
返回